kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california.
Company profile
Ticker
KNTE
Exchange
Website
CEO
Nima Farzan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
824566526
KNTE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
17 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Apr 24
POSASR
Automatic shelf registration (post-effective amendment)
3 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
3 Apr 24
SC 14D9/A
Tender offer solicitation (amended)
3 Apr 24
25-NSE
Exchange delisting
3 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
3 Apr 24
SC 14D9/A
Tender offer solicitation (amended)
22 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.03 mm | 52.03 mm | 52.03 mm | 52.03 mm | 52.03 mm | 52.03 mm |
Cash burn (monthly) | (no burn) | 775.75 k | 11.03 mm | 11.21 mm | 8.51 mm | 8.87 mm |
Cash used (since last report) | n/a | 5.18 mm | 73.70 mm | 74.93 mm | 56.87 mm | 59.26 mm |
Cash remaining | n/a | 46.85 mm | -21.67 mm | -22.89 mm | -4.84 mm | -7.23 mm |
Runway (months of cash) | n/a | 60.4 | -2.0 | -2.0 | -0.6 | -0.8 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 9 |
Closed positions | 20 |
Increased positions | 15 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 51.62 bn |
Total shares | 52.69 mm |
Total puts | 1.90 k |
Total calls | 2.50 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Foresite Capital Fund IV | 9.67 mm | $29.98 mm |
Foresite Capital Management IV | 9.67 mm | $13.54 bn |
Orbimed Advisors | 8.01 mm | $11.21 bn |
Foresite Capital Management V | 3.53 mm | $4.94 bn |
Nextech V Oncology S.C.S., SICAV-SIF | 2.33 mm | $0.00 |
Nextech Invest | 2.33 mm | $3.26 bn |
Vida Ventures | 2.21 mm | $0.00 |
Vida Ventures Advisors | 2.21 mm | $3.09 bn |
Lynx1 Capital Management | 2.00 mm | $2.80 bn |
Viking Global Investors | 1.82 mm | $2.55 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Foresite Capital Management IV | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 520,711 | 0.00 | 0 |
3 Apr 24 | Foresite Capital Management IV | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 3,525,957 | 0.00 | 0 |
3 Apr 24 | Foresite Capital Management IV | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 9,671,643 | 0.00 | 0 |
3 Apr 24 | Orbimed Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 450,000 | 0.00 | 0 |
3 Apr 24 | Orbimed Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 84,599 | 0.00 | 0 |
3 Apr 24 | Orbimed Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 1,368,338 | 0.00 | 0 |
3 Apr 24 | Orbimed Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 4,738,453 | 0.00 | 0 |
3 Apr 24 | Orbimed Advisors | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 1,368,339 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 450,000 | 0.00 | 0 |
3 Apr 24 | Gordon Carl L | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 84,599 | 0.00 | 0 |
News
XOMA Corp Entered Into A Merger Agreement To Acquire Kinnate Biopharma For A Base Cash Price Per Share Of $2.3352 Per Share And An Additional Cash Amount Of Not More Than $0.2527 Per Share
19 Mar 24
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, To Pierre Fabre Laboratories For A Total Consideration Of Up To $31M
1 Mar 24
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
16 Feb 24
Press releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, SCTL, KNTE
20 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE
18 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FANG, FREE, KNTE
16 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, DOOR, HMST
13 Mar 24
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
13 Mar 24